# ARPA-H Awards Stanford $12.9M for Implantable Lymphatic Vessel Regeneration Device

> financing · REPORTED · 2026-04-10

ARPA-H awarded Stanford Medicine researcher Stanley Rockson and team up to $12.9 million to develop a small implantable device, approximately half a centimeter in size, that can be placed at the site of lymphatic injury during cancer surgery and paired with medication to encourage regeneration of lymphatic vessels and prevent chronic lymphedema. The award is part of ARPA-H's GLIDE program targeting lymphatic medicine.

About Stanford Medicine / ARPA-H GLIDE Program: Stanford Medicine's lymphatic research program, under the ARPA-H GLIDE initiative, is developing a miniaturized implantable device designed to regenerate lymphatic vessels in cancer surgery patients and prevent the onset of chronic lymphedema.

- Company: Stanford Medicine / ARPA-H GLIDE Program
- Sector: medical devices
- Primary source: https://med.stanford.edu/news/all-news/2026/04/arpa-h-contracts.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.